New obesity drug tested for safety with everyday medications
NCT ID NCT07550816
First seen May 05, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This early-stage study looks at how an experimental long-acting drug called ZT002 affects the way the body processes four common medicines (metformin, warfarin, rosuvastatin, and digoxin) in overweight and obese adults aged 18 to 45. About 60 healthy volunteers will take these medicines with and without ZT002 to see if there are any changes. The goal is to gather safety information, not to treat or cure obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Second Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.